Amphstar Pharmaceuticals, Inc. (AMPH)
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-04
$23.18-2.77%
Close 2026-09-04 · 1-day change
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-04
QuarterlyIQ Insights · AMPH
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | |||||||||||||
| Revenues | 730.0 | 719.9 | 732.0 | 644.4 | 499.0 | 437.8 | 349.8 | 322.4 | 294.7 | 240.2 | 255.2 | 251.5 | 210.5 |
| Total Revenues | 730.0 | 719.9 | 732.0 | 644.4 | 499.0 | 437.8 | 349.8 | 322.4 | 294.7 | 240.2 | 255.2 | 251.5 | 210.5 |
| Cost of Revenues | 381.9 | 363.8 | 358.1 | 293.3 | 250.1 | 238.0 | 206.5 | 190.4 | 187.7 | 149.7 | 151.0 | 174.2 | 159.2 |
| Gross Profit | 348.1 | 356.1 | 373.9 | 351.1 | 248.9 | 199.7 | 143.3 | 131.9 | 107.0 | 90.5 | 104.2 | 77.3 | 51.3 |
| Operating Expenses & Income | |||||||||||||
| R&D Expenses | 94.6 | 85.8 | 73.9 | 73.7 | 74.8 | 60.9 | 67.2 | 68.9 | 57.6 | 43.5 | 41.5 | 37.3 | 28.9 |
| Operating Income | 114.3 | 140.4 | 205.4 | 197.0 | 107.5 | 69.9 | 11.0 | (0.0) | (8.6) | (1.3) | 15.4 | (6.9) | (18.0) |
| Earnings from Continuing Operations | |||||||||||||
| Interest Expense | — | 25.5 | 30.3 | 27.2 | 1.8 | 0.9 | 0.4 | 0.1 | 0.2 | 0.8 | 1.0 | 1.0 | 0.6 |
| Interest & Investment Income | 9.4 | 8.7 | 10.6 | 5.5 | 1.3 | 0.6 | 0.6 | 1.0 | 0.5 | 0.4 | 0.3 | 0.3 | 0.2 |
| Net Interest Expenses | — | — | — | 21.7 | 0.5 | 0.3 | (0.3) | (0.9) | (0.2) | 0.4 | 0.8 | 0.7 | 0.4 |
| Other Non-Operating Income / Expenses | (12.3) | (16.8) | (15.7) | (25.6) | 8.5 | 14.3 | (6.3) | 60.3 | (1.3) | 2.5 | (0.7) | (3.5) | (0.2) |
| Asset Writedown | — | — | — | — | — | — | — | — | — | — | — | — | 0.4 |
| EBT, Incl. Unusual Items | 102.0 | 123.6 | 189.8 | 171.4 | 116.0 | 84.1 | 4.6 | 60.2 | (9.9) | 1.2 | 14.6 | (10.4) | (18.1) |
| Income Tax Expense | 23.5 | 25.5 | 29.7 | 31.8 | 23.5 | 20.6 | 3.5 | 13.7 | (3.3) | (2.4) | 4.8 | (7.6) | (7.4) |
| Net Income | |||||||||||||
| Minority Interest | — | — | — | — | — | 1.2 | (0.3) | (2.4) | (0.9) | — | — | — | — |
| Net Income | 78.5 | 98.1 | 159.5 | 137.5 | 91.4 | 62.1 | 1.4 | 48.9 | (5.7) | 3.6 | 9.8 | (2.8) | (10.7) |
| Per Share | |||||||||||||
| Basic EPS | 1.80 | 2.10 | 3.29 | 2.85 | 1.88 | 1.30 | 0.03 | 1.04 | (0.12) | 0.08 | 0.22 | (0.06) | (0.25) |
| Diluted EPS | 1.78 | 2.03 | 3.06 | 2.60 | 1.74 | 1.25 | 0.03 | 0.98 | (0.12) | 0.08 | 0.21 | (0.06) | (0.25) |
| Revenue per Share | 16.51 | — | — | — | — | — | — | — | — | — | — | — | — |
| Basic Weighted Avg Shares | 43.6 | 46.7 | 48.4 | 48.3 | 48.6 | 47.8 | 47.0 | 47.0 | 46.4 | 46.1 | 45.4 | 45.0 | 42.0 |
| Diluted Weighted Avg Shares | 44.2 | 48.2 | 52.1 | 53.0 | 52.4 | 49.8 | 49.1 | 49.9 | 46.4 | 48.4 | 47.5 | 45.0 | 42.0 |
| Supplemental | |||||||||||||
| EBITDA | — | — | — | 222.7 | 120.1 | 80.1 | 20.0 | 7.0 | — | — | — | — | — |
| EBIT | 114.3 | 140.4 | 205.4 | 197.0 | 107.5 | 69.9 | 11.0 | (0.0) | (8.6) | (1.3) | 15.4 | (6.9) | (18.0) |
| Effective Tax Rate | 23.0% | — | — | 18.6% | 20.2% | 24.5% | 76.3% | 22.8% | 32.9% | -192.0% | 32.9% | 73.1% | 41.0% |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.